{
  "title": "Sample MASLD/MASH systematic review — Resmetirom + FGF21 analogs in advanced fibrosis",
  "authors": ["Sample Author A", "Sample Author B"],
  "year": 2026,
  "registration": "PROSPERO CRD42026-MOCK-001",
  "search_date": "2026-03-15",
  "disclaimer": "Mock list for cross-reference demonstration only.",
  "included_papers": [
    {"pmid": "39812301", "doi": "10.1002/hep.32781", "label": "Kim 2025 — resmetirom phase 3 extension"},
    {"pmid": "39712219", "doi": "10.1016/j.jhep.2024.11.008", "label": "Tanaka 2024 — pegozafermin"},
    {"pmid": "39310775", "doi": "10.1002/hep.31988", "label": "Kim 2023 — firsocostat MASH"},
    {"pmid": "39210664", "doi": "10.1016/j.jhep.2023.08.014", "label": "Dupont 2023 — elafibranor RESOLVE-IT"},
    {"pmid": "38910331", "doi": "10.1002/hep.31654", "label": "Kim 2022 — resmetirom MAESTRO-NASH"},
    {"pmid": "38810220", "doi": "10.1016/j.jhep.2022.10.011", "label": "Andersen 2022 — semaglutide MASH"},
    {"pmid": "38509997", "doi": "10.1111/liv.15234", "label": "Tanaka 2022 — pegbelfermin PK"},
    {"pmid": "38409886", "doi": "10.1002/hep.31200", "label": "Kim 2022 — ACC+THR-β combo"},
    {"pmid": "37909331", "doi": "10.1002/hep.30887", "label": "Kim 2021 — resmetirom F1"},
    {"pmid": "37808220", "doi": "10.1016/j.jhep.2021.06.011", "label": "Garcia 2021 — CK-18 cohort (not in DB, control)"},
    {"pmid": "37408886", "doi": "10.1002/hep.30200", "label": "Kim 2020 — MASH obeticholic + statin"},
    {"pmid": "36808220", "doi": "10.1016/j.jhep.2019.02.011", "label": "Tanaka 2019 — pegbelfermin phase 2b"},
    {"pmid": "11111111", "doi": "10.0000/clean-paper-001", "label": "Clean paper 1 (not retracted, control)"},
    {"pmid": "22222222", "doi": "10.0000/clean-paper-002", "label": "Clean paper 2 (not retracted, control)"}
  ]
}